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E
stimates indicate that by 2020, more than threequarters of a million people in the United States will have end-stage renal disease (ESRD), leading to increased requirements for dialysis or kidney transplant. 1 Treatment for chronic kidney failure accounted for more than $30 billion, or 8%, of all Medicare expenditures in 2009, yet outcomes remain poor; mortality rates are more than 6 times higher in patients with ESRD than in the non-ESRD population.
creased estimated glomerular filtration rate (eGFR). In contrast, relatively few studies have focused on identifying risk factors for ESRD in people who still have a normal serum creatinine level and a correspondingly preserved eGFR. In one such study of volunteers in a health assessment program, participants were all insured and lived in Northern California, limiting its generalizability. 11 Other population-based cohort studies lacked baseline kidney function measurements, [12] [13] [14] precluding identification of participants with underlying kidney disease at the study start.
To address some of the limitations of these previous studies, we conducted a study of participants in the Kidney Early Evaluation Program (KEEP), a nationwide community-based health screening study of people at high risk of kidney disease, with eGFR Ն60 mL/min/1.73 m 2 . The primary objective was to identify risk factors for developing treated chronic kidney failure in participants with preserved eGFR. Because risk factors for developing treated chronic kidney failure vary by albuminuria status in patients with moderate to severe decreases in eGFR, 15, 16 we conducted all analyses stratified by albuminuria status.
METHODS

Study Population
KEEP is a free community-based voluntary screening program run by the National Kidney Foundation that was launched in August 2000 and is designed to identify individuals at increased risk of kidney disease and encourage follow-up care. 17 KEEP screenings are conducted in urban and rural locations throughout the United States through each state's National Kidney Foundation affiliate. During KEEP screening, participants complete a questionnaire to assess demographic characteristics, personal and family medical history, and health behaviors. Blood pressure, height, and weight are recorded. In this study, we included eligible KEEP participants screened from August 2000 to December 31, 2011. Because we were interested in studying participants with preserved eGFR, we excluded participants with eGFR Ͻ60 mL/min/ 1.73 m 2 and participants with self-reported history of kidney transplantation, leaving 123,058 participants for our analysis. KEEP was approved by the Institutional Review Board at Hennepin County Medical Center, Minneapolis, MN.
Estimation of Kidney Function
Blood and urine specimens were collected for determination of serum creatinine level and albuminuria. Serum creatinine was measured by Satellite Laboratory Services (Redwood City, CA) using the Olympus 5431 (Olympus Optical) and by Consolidated Laboratory Services, Van Nuys, CA, using the Abbott Architect c8000 (Abbott Laboratories) and calibrated to the Cleveland Clinic. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 18 and albumin values Ͼ30 mg/L were considered positive for microalbuminuria. From April 2002 to the present, urine albumincreatinine ratio also was measured and reported as Ͻ30, 30-300, or Ͼ300 mg/g. For the present analysis, participants were categorized as having albuminuria if they had a positive urine dipstick for albumin using either assay or albumin-creatinine ratio of 30-300 or Ͼ300 mg/g.
Outcome
The primary outcome was incident ESRD defined as initiation of dialysis therapy or kidney transplant. We ascertained ESRD by linking KEEP with the US Renal Data Systems database, which includes Ͼ90% of patients with incident ESRD. 1 We followed up participants until December 31, 2011, or time of death as reported by the National Death Index.
Risk Factors for ESRD
Demographic information for age, sex, and race/ethnicity was recorded at the screening session. Education was categorized as fewer than 12 or 12 or more years. Current smoking status and health insurance status were categorized as yes or no. Diabetes mellitus was defined by self-report, self-reported use of medications for diabetes, fasting glucose values Ն126 mg/dL, or nonfasting glucose levels Ն200 mg/dL. Cardiovascular disease was defined as self-report of cardiac angioplasty, cardiac bypass surgery, heart attack, heart failure, abnormal heart rhythm, stroke, or peripheral vascular disease. Hypertension was defined by selfreport or self-reported use of antihypertensive medications. Hyperlipidemia was defined by self-report, self-reported use of lipidlowering medications, or fasting total cholesterol level Ͼ200 mg/dL. Family history of kidney disease and diabetes also was ascertained.
Body mass index was calculated from the recorded height and weight. Blood pressure was measured with the participant seated after at least 5 minutes of rest. If the first systolic blood pressure (SBP) reading was Ն140 mm Hg or the first diastolic blood pressure reading was Ն90 mm Hg, the participant rested for an additional 5 minutes and blood pressure was measured again on the same arm.
Statistical Analysis
We conducted all analyses after stratifying by baseline albuminuria status. Baseline characteristics were described using proportions or mean Ϯ standard deviation, as appropriate. Because death is a competing risk for the development of ESRD, we estimated the subdistribution hazard ratio (HR) using the Fine-Gray 19 method, which accounts for competing events and allows for multivariable adjustment. We examined the following demographic and comorbid conditions: age (per 10 years older), sex, race/ethnicity, current smoking status, education, health insurance, diabetes mellitus, cardiovascular disease, hyperlipidemia, family history of kidney disease, family history of diabetes, eGFR (per-10 mL/min/1.73m 2 lower), SBP (per 10-mm Hg higher), and body mass index (per 5-kg/m 2 higher). To avoid collinearity, self-reported hypertension and diastolic blood pressure were not included in the multivariable models. We created a missing category for variables with missing data. Except for hyperlipidemia (for which data were available only after 2005), missing data constituted Ͻ6% for all variables. We considered 2-tailed P Ͻ 0.05 statistically significant. All analyses were conducted with SAS, version 9.2 (SAS Institute Inc). smokers, with a higher prevalence of diabetes mellitus, cardiovascular disease, and hypertension compared with participants with preserved eGFR without albuminuria (Table 1) . During an overall median of 4.8 years of follow-up (interquartile range, 4.1 years), 126 participants with albuminuria developed treated chronic kidney failure (16/10,000 patient-years), compared with 56 participants without albuminuria (1.1/ 10,000 patient-years); 866 participants with albuminuria (11.0/10,000 patient-years) and 2,556 participants without albuminuria (4.9/10,000 patient-years) died before developing treated chronic kidney failure.
The crude incidence of ESRD was approximately 10-to 20-fold higher for participants with albuminuria than for participants without albuminuria in each subgroup (Table 2 ). For example, for all participants with diabetes mellitus, the crude incidence of ESRD was 8.6 events per 10,000 patient-years. However, for the subset of participants with both diabetes mellitus and albuminuria, the crude incidence of ESRD was 35.1 events per 10,000 patient-years, compared with 3.0 events per 10,000 patient-years for the subset with diabetes mellitus without albuminuria. The crude incidence of ESRD for participants with neither diabetes mellitus nor albuminuria was only 0.4 events per 10,000 patient-years.
In univariate analysis, risk factors for ESRD in participants with and without albuminuria were similar (Table 3) . For example, diabetes mellitus was associated with an 8.2-fold (95% confidence interval [CI], 5.2-13.0) higher risk of developing ESRD in participants with albuminuria and an 8.1-fold (95% CI, 4.5-14.8) higher risk in participants without albuminuria. One exception was for non-Hispanic other race, which was associated with a higher risk of treated chronic kidney failure in participants with albuminuria only (Table 3) .
After multivariable adjustment, black race, diabetes mellitus, and lower eGFR remained significantly associated with developing treated chronic kidney failure irrespective of albuminuria status (Fig 1) . Higher SBP and non-Hispanic other race remained 
DISCUSSION
We sought to identify risk factors for developing treated chronic kidney failure in people with preserved eGFR with and without albuminuria, a population for which relatively little information currently is available. We show that in a diverse high-risk cohort of KEEP participants with eGFR Ն60 mL/min/1.73 m 2 , black race, diabetes mellitus, lower eGFR, and higher SBP are associated with developing treated chronic kidney failure. Moreover, crude rates of ESRD for participants with one of these risk factors and albuminuria were 10-to 20-fold higher than for participants with one of these risk factors but without albuminuria. Our results support the recommendations made by national societies that advocate testing for kidney disease in patients with diabetes mellitus and cardiovascular disease risk factors. [20] [21] [22] However, actual rates of testing for kidney disease in clinical practice remain low. An audit of patients with diabetes mellitus and hypertension showed that only 53% had serum creatinine checked in the prior 24 months and 29% had urine tested for proteinuria in the prior 12 months. 23 Similarly, in the ADD-CKD (Awareness, Detection, and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease) Study, only 12.1% of participants with kidney disease were identified correctly as such by their providers. 24 We found an increased risk of developing treated ESRD with higher SBP in participants with and without albuminuria, although the association was attenuated and no longer statistically significant in participants without albuminuria after multivariable adjustment. Our study complements our recent report of KEEP participants with eGFR Ͻ60 mL/min/1.73 m 2 , which also demonstrated an increased risk of developing ESRD with SBP Ն150 mm Hg after adjustment for other factors. 25 In a cohort of insured residents of Northern California with preserved eGFR but no albuminuria, Hsu et al 11 found a 2.6-and 3.8-fold higher adjusted risk of developing ESRD with SBP of 140-159 and 160-179 mm Hg, respectively, and our results extend those findings to the more geographically and socioeconomically diverse KEEP cohort. However, in the African American Study of Kidney Disease and Hypertension (AASK), one of the few clinical trials to evaluate blood pressure treatment targets in chronic kidney disease, 16 randomization to more intensive treatment of hypertension (target mean arterial pressure Ͻ92 mm Hg) did not reduce the rate of kidney disease progression compared with participants in the standard group (target mean arterial pressure of 102-107 mm Hg). However, because all participants in AASK had established nondiabetic kidney disease (measured GFR of 20-65 mL/min/1.73 m 2 ), whether those results are applicable to people with preserved eGFR is not known.
Although all participants in the present analysis had eGFR Ն60 mL/min/1.73 m 2 , each 10-mL/min/ 1.73 m 2 lower level in baseline eGFR was associated with a 20%-40% higher risk of developing treated chronic kidney failure irrespective of albuminuria status. Our results are consistent with several previous studies indicating that even slight decrements in eGFR are associated with higher risk of developing ESRD. 9, 15, 26 For example, the Atherosclerosis Risk in Communities (ARIC) Study 9 examined 15,324 white We found a significant 19%-40% lower risk of developing treated ESRD for each 10-year-older age in adjusted models, consistent with other observational studies. 10, 26, 27 These results likely are explained because each 10-year increase in age was associated with a 2-fold higher risk of death before developing treated ESRD. Moreover, we examined treated ESRD as the primary end point and were unable to identify participants who may have chosen not to undergo renal replacement therapy despite a low eGFR, a decision made more commonly by older patients. 28 Although our study has several strengths, it also has several limitations. First, we relied on a single measurement of serum creatinine and albuminuria, possibly leading to misclassification of some participants. However, as a screening tool to identify people at high risk of developing ESRD, a single measurement may be appropriate. Second, we did not have information for medications, specifically angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, which can slow the development of ESRD. 29, 30 Finally, our median follow-up time was relatively short, yet we still found an incidence rate of ESRD approximately twice that reported by studies based on general unselected cohorts.
12, 26 The relatively rapid development of ESRD in our cohort, all of whom started the study with eGFR Ն60 mL/min/1.73 m 2 , may have been precipitated by episodes of acute kidney injury from hospitalization, use of nephrotoxic medications, or other acute events that we were unable to identify.
In conclusion, we identified several risk factors for developing ESRD in participants with preserved eGFR with and without albuminuria, including diabetes mellitus, higher SBP, black race, and lower eGFR. Our findings have important clinical implications because they help identify high-risk people who may benefit from kidney disease screening.
